MedTrace Logo

S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction

NCT05553886 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-11-03

No results posted yet for this study

Summary

A randomized, double-blind, positive-drug parallel controlled, multicenter phase III trial of the efficacy and safety of S086 tablets in patients with chronic heart failure with reduced ejection fraction (HFrEF)

Conditions

  • Chronic Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug

To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug

Sponsors & Collaborators

  • Shenzhen People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-21
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05553886 on ClinicalTrials.gov